Characteristics of the 2 study cohorts
| Characteristic | No. (%) of patients* | |
|---|---|---|
| Cohort 1 n = 1058 | Cohort 2 n = 5974 | |
| Age, yr, mean ± SD | 67 ± 17 | 68 ± 17 |
| Female sex | 558 (52.7) | 3025 (50.6) |
| Hypertension | 744 (70.3) | 4045 (67.7) |
| Diabetes mellitus | 312 (29.4) | 1961 (32.8) |
| History of myocardial infarction | 378 (35.7) | 674 (11.3) |
| History of PCI or CABG | 236 (22.3) | 453 (7.6) |
| History of peripheral vascular disease | 75 (7.1) | 742 (12.4) |
| Glucose concentration, mmol/L, mean ± SD | 7.4 ± 3.6 | 7.6 ± 4.4 |
| eGFR, mL/min per 1.73 m2, mean ± SD | 72 ± 27 | 69 ± 27 |
| hs-cTnI concentration at presentation < 99th percentile cut-off† | 842 (79.6) | 4698 (78.6) |
| 30-day MACE | 205 (19.4) | 871(14.6) |
Note: CABG = coronary artery bypass grafting, eGFR = estimated glomerular filtration rate, hs-cTNI = high-sensitivity cardiac troponin I, MACE = major adverse cardiac event, PCI = percutaneous coronary intervention, SD = standard deviation.
↵* Unless indicated otherwise.
↵† 99th percentile upper reference limit is 11 ng/L for Ortho hs-cTnI assay and 26 ng/L for Abbott hs-cTnI assay.